(Q50522258)

English

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.

scientific article published on 22 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. (English)

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

1 reference

based on heuristic

inferred from title

Kazuaki Chayama

10

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

11

object named as

Masataka Tsuge

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Hiromitsu Kumada

20

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Yoshiyuki Suzuki

3

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Mariko Kobayashi

4

object named as

Mariko Kobayashi

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Yasuhito Tanaka

5

object named as

Yasuhito Tanaka

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

2

object named as

Eiji Tanaka

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

author name string

Akihiro Matsumoto

1

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Noboru Shinkai

6

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Shuhei Hige

7

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Hiroshi Yatsuhashi

8

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Shinya Nagaoka

9

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Osamu Yokosuka

12

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Fumio Imazeki

13

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Shuhei Nishiguchi

14

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Masaki Saito

15

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Kei Fujiwara

16

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Nobuyuki Torii

17

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Naoki Hiramatsu

18

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Yoshiyasu Karino

19

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

publication date

22 November 2011

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Hepatology Research

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

42

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

139-149

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

2

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Management of hepatitis B: summary of a clinical research workshop

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Hepatitis B reactivation after lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Chronic hepatitis B: back to the future with HBsAg

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00910.X

21 January 2018

Identifiers

10.1111/J.1872-034X.2011.00910.X

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

1 reference

Europe PubMed Central

14 March 2018

http://europepmc.org/abstract/MED/22103237

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50522258&oldid=1779215110"